PetCaseFinder

Peer-reviewed veterinary case report

New chewable tablet Credelio Quattro treats roundworms in dogs

By Charles, Samuel et al.·Published in Parasites & vectors·2025·Elanco Animal Health, United States·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Efficacy of a novel chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel against Toxocara canis and Toxascaris leonina infections in dogs.

Species:
dog
Canine giardiasisStomach & digestionDogs

Plain-English summary

A group of dogs with roundworm infections, specifically Toxocara canis and Toxascaris leonina, were treated with a new chewable tablet called Credelio Quattro. This treatment was found to be very effective, eliminating over 97% of the roundworms and reducing fecal egg counts by more than 98%. While some dogs experienced mild digestive issues like diarrhea and vomiting, the overall safety of the treatment was confirmed. After just one dose, the dogs showed significant improvement, making Credelio Quattro a promising option for treating these common infections.

People also search for: dog roundworm treatment · Toxocara canis symptoms in dogs · Credelio Quattro for dogs

Abstract

BACKGROUND: Roundworms such as Toxascaris leonina and Toxocara canis are routinely diagnosed in dogs globally, especially in dogs 6 months of age or younger. Toxocara canis is zoonotic, can cause significant disease in dogs, and is the causative agent of toxocariasis in humans. To protect both animal and human health, it is imperative that Toxocara canis infections are effectively treated and controlled to minimize the risk of transmission. The following studies were performed to demonstrate the effectiveness and safety of a novel, combination chewable tablet (Credelio Quattro) containing the minimum effective dosages of lotilaner (20.0 mg/kg), moxidectin (0.02 mg/kg), praziquantel (5.0 mg/kg), and pyrantel (5.0 mg/kg) for the treatment and control of T. canis and T. leonina infections in dogs. METHODS: Six well-controlled studies were performed. Two studies each evaluated Credelio Quattro against immature adult T. canis, adult T. canis, and adult T. leonina infections. Post-treatment efficacy was calculated from necropsy worm counts, and fecal egg count reduction was determined 10 days post-treatment in studies evaluating experimentally induced or naturally acquired adult infections. RESULTS: Credelio Quattro was safe and ≥ 97.9% effective against immature adult stages and ≥ 97.0% effective against adult stages of induced and natural T. canis infections in dogs. After treatment with Credelio Quattro, fecal egg counts were reduced by ≥ 98.8% in T. canis-infected dogs. In both experimentally induced and naturally acquired adult T. leonina infections in dogs, Credelio Quattro was safe and 100% effective in eliminating adult worms and provided 100% reduction in fecal egg counts post-treatment. The most common adverse events reported included digestive tract disorders such as diarrhea, mucus and/or blood in feces, vomiting, and expelled ascarid worms, which occurred in both control- and treated-groups. CONCLUSIONS: These laboratory studies confirm the effectiveness and safety of a single dose of Credelio Quattro, administered at the minimum dosages of 20 mg/kg lotilaner, 0.02 mg/kg moxidectin, 5 mg/kg praziquantel, and 5 mg/kg pyrantel, for the treatment and control of immature adult and adult T. canis and adult T. leonina in dogs.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40836259/